UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 141

Sortiert nach

Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries

Journal of hepatology, 2011-07, Vol.55 (1), p.183-191

Hadziyannis, Stephanos J

2011

Link zum Volltext

Verfügbarkeit prüfen

Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B

Hepatology (Baltimore, Md.), 2007-02, Vol.45 (2), p.307-313

2007

Link zum Volltext

Verfügbarkeit prüfen

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B

Virology journal, 2022-01, Vol.19 (1), p.22-22, Article 22

2022

Link zum Volltext

Verfügbarkeit prüfen

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients

Hepatology (Baltimore, Md.), 2006-09, Vol.44 (3), p.694-702

2006

Link zum Volltext

Verfügbarkeit prüfen

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen

Clinical gastroenterology and hepatology, 2016-10, Vol.14 (10), p.1499-1501

Hadziyannis, Stephanos J., MD

2016

Link zum Volltext

Verfügbarkeit prüfen

Milestones and perspectives in viral hepatitis B

Liver international, 2011-01, Vol.31 (s1), p.129-134

Hadziyannis, Stephanos J.

2011

Link zum Volltext

Verfügbarkeit prüfen

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

Gastroenterology (New York, N.Y. 1943), 2012-09, Vol.143 (3), p.629-636.e1

2012

Link zum Volltext

Verfügbarkeit prüfen

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

The New England journal of medicine, 2003-02, Vol.348 (9), p.800-807

2003

Link zum Volltext

Verfügbarkeit prüfen

Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels

Antiviral therapy, 2007, Vol.12 (1), p.73-82

2007

Link zum Volltext

Verfügbarkeit prüfen

The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

Advances in Pharmacology, 2013, Vol.67, p.247-291

2013

Link zum Volltext

Verfügbarkeit prüfen

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

Hepatology (Baltimore, Md.), 2002-07, Vol.36 (1), p.219-226

2002

Link zum Volltext

Verfügbarkeit prüfen

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

Journal of hepatology, 2011-07, Vol.55 (1), p.69-75

2011

Link zum Volltext

Verfügbarkeit prüfen

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Journal of hepatology, 2013-12, Vol.59 (6), p.1153-1159

2013

Link zum Volltext

Verfügbarkeit prüfen

Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis

European journal of gastroenterology & hepatology, 2008-01, Vol.20 (1), p.5-9

2008

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B e antigen—negative chronic hepatitis B

Hepatology (Baltimore, Md.), 2001-10, Vol.34 (4), p.617-624

2001

Link zum Volltext

Verfügbarkeit prüfen

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

Gastroenterology (New York, N.Y. 1943), 2006-12, Vol.131 (6), p.1743-1751

2006

Link zum Volltext

Verfügbarkeit prüfen

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Hepatology (Baltimore, Md.), 2006-05, Vol.43 (5), p.954-960

2006

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

Seminars in liver disease, 2006-05, Vol.26 (2), p.130-141

2006

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

Hepatology (Baltimore, Md.), 2010-02, Vol.51 (2), p.388-397

2010

Link zum Volltext

Verfügbarkeit prüfen

Erratum to: “Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries” [J Hepatol 2011;55:183–191]

Journal of hepatology, 2013-05, Vol.58 (5), p.1062-1062

Hadziyannis, Stephanos J

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Journal of hepatology, 2011-06, Vol.54 (6), p.1250-1262

2011

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

The New England journal of medicine, 2005-06, Vol.352 (26), p.2673-2681

2005

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility

Expert review of gastroenterology & hepatology, 2014-02, Vol.8 (2), p.185-195

2014

Link zum Volltext

Verfügbarkeit prüfen

Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

Gastroenterology (New York, N.Y. 1943), 2001-07, Vol.121 (1), p.101-109

2001

Link zum Volltext

Verfügbarkeit prüfen

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

Journal of hepatology, 2010-06, Vol.52 (6), p.832-838

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 141

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(140)
Reviews
(1)

Sprache

Englisch
(140)
Japanisch
(17)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(92)
Science & Technology
(91)
Life Sciences & Biomedicine
(90)
Gastroenterology & Hepatology
(72)
Biological And Medical Sciences
(60)
Medical Sciences
(57)
Male
(54)
Female
(49)
Adult
(44)
Middle Aged
(39)
Antiviral Agents - Therapeutic Use
(35)
Hepatitis B, Chronic - Drug Therapy
(32)
Infectious Diseases
(29)
Interferon-Alpha - Therapeutic Use
(27)
Human Viral Diseases
(25)
Viral Diseases
(25)
Viral Hepatitis
(25)
Aged
(23)
Recombinant Proteins
(21)
Gastroenterology. Liver. Pancreas. Abdomen
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries

Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B

Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B

Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen

Milestones and perspectives in viral hepatitis B

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels

The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis

Hepatitis B e antigen—negative chronic hepatitis B

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

Erratum to: “Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries” [J Hepatol 2011;55:183–191]

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B

Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility

Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

Suchergebnisse filtern